Group 1: Company Overview - Yuntian Lifei Technology Co., Ltd. (Yuntian Lifei) submitted its prospectus to the Hong Kong Stock Exchange on July 30, 2025, aiming for a main board listing, following its successful debut on the STAR Market in 2023 [3] - Founded in 2014, Yuntian Lifei focuses on the research, design, and commercialization of AI inference chips, offering products and services for enterprise, consumer, and industry applications [3][4] - Yuntian Lifei is ranked among the top three providers of AI inference chip products and services in China, with significant revenue growth projected in the AI inference chip market [4] Group 2: Financial Performance - Yuntian Lifei's revenue for 2022, 2023, and 2024 was reported at 546 million, 506 million, and 917 million respectively, with a year-on-year revenue increase of over 168% to 264 million in Q1 of the current year [4] - The market size for AI inference chip products and services in China is expected to grow from 11.3 billion in 2020 to 162.6 billion by 2024, with a compound annual growth rate (CAGR) of 94.9% [4] Group 3: Industry Trends - The company plans to increase investment in AI inference chips, focusing on edge computing, cloud-based large model inference, and embodied intelligence [4] - Blue Arrow Aerospace signed a counseling agreement with CICC on July 25, 2023, to initiate its listing process on the STAR Market, potentially becoming the first commercial aerospace company listed on the STAR Market [6] - Founded in 2015, Blue Arrow Aerospace aims to create a comprehensive technology ecosystem centered around medium and large liquid oxygen-methane launch vehicles, having successfully launched the world's first liquid oxygen-methane rocket [6][7] Group 4: Biotechnology Sector - Beijing Yimiao Shenzhou Biopharmaceutical Co., Ltd. (Yimiao Shenzhou) signed a counseling agreement with CITIC Securities on July 23, 2023, to start its listing process on the STAR Market [10] - Established in 2015, Yimiao Shenzhou specializes in innovative gene cell drug technology for treating major diseases, with a focus on CAR-T therapies for various cancers [10][11] - The company has completed 10 rounds of financing, attracting investments from multiple venture capital firms and funds [12]

Group 1 - Beijing Yimiao Shenzhou Biopharmaceutical Co., Ltd. (referred to as "Yimiao Shenzhou") completed its IPO counseling record with the Beijing Securities Regulatory Bureau, aiming for an IPO on the Sci-Tech Innovation Board, with CITIC Securities as the counseling institution [1] - The company was established on April 14, 2015, with a registered capital of 30 million RMB, focusing on gene cell drugs for the treatment of malignant tumors [1] - The controlling shareholder is He Ting, who directly and indirectly controls 21.92% of the company's shares, and he graduated from Tsinghua University with a background in cancer biology [1] Group 2 - The company has undertaken over ten national and provincial scientific research projects, collaborating with top hospitals such as Beijing Cancer Hospital, Tsinghua Changgung Hospital, Peking Union Medical College Hospital, and others for CAR-T drug clinical research [2] - Yimiao Shenzhou has been recognized as a national high-tech enterprise, a postdoctoral research workstation, a Beijing engineering research center, a specialized and innovative enterprise in Beijing, and a CAR-T joint research and development center [2]

Core Viewpoint - Beijing Yimiao Shenzhou Biopharmaceutical Co., Ltd. is advancing its IPO process on the Sci-Tech Innovation Board, having signed a counseling agreement with CITIC Securities on July 23 this year [2]. Company Overview - Founded in 2015, Yimiao Shenzhou focuses on innovative drug development using original research gene cell therapy for major diseases such as cancer and autoimmune diseases [2]. - The company has developed a one-stop platform for gene cell drug research and industrialization, with 7 clinical trial approvals in China and 1 in the United States for CAR-T new drugs [2]. Product Pipeline - The research pipeline includes treatments for hematological tumors such as lymphoma, leukemia, and myeloma, as well as solid tumors like liver cancer, gastric cancer, colorectal cancer, and melanoma [2]. - The CAR-T product IM19 targets relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) and has submitted a New Drug Application (NDA) in China, which has been accepted [3]. - IM96 is the only CAR-T candidate drug globally that has received clinical trial approval in both China and the United States, specifically targeting GUCY2C [4]. Market Position - IM19's innovative CAR molecular design and production process provide more specific therapeutic effects, significantly improving survival time and quality of life for r/r DLBCL patients, thus filling a market gap for domestically developed CAR-T therapies in China [3]. - IM96 has been approved for treating colorectal cancer in China, marking it as the first CAR-T candidate for this indication in the country [4]. Financing and Investment - Yimiao Shenzhou has completed a total of 10 financing rounds since its establishment, with investors including Foothill Ventures, Tsinghua x-lab, and several other venture capital firms and funds [4].